Literature DB >> 21903025

Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression.

Jerome Sarris1, David Mischoulon, Isaac Schweitzer.   

Abstract

OBJECTIVE: Studies using augmentation of pharmacotherapies with omega-3 in bipolar disorder have been conducted; however, to date a specific meta-analysis in this area has not been published. Thus, we present the significant findings from meta-analyses of omega-3 in the treatment of bipolar depression and bipolar mania. DATA SOURCES: PubMed, CINAHL, Web of Science, and Cochrane Library databases were searched for clinical trials up to September 1, 2010, using the search terms bipolar disorder OR bipolar depression OR bipolar mania OR mania OR hypomania OR cyclothymia with the search terms omega 3 OR essential fatty acids OR polyunsaturated fatty acids OR DHA OR EPA OR fish oil OR flax oil. Clinical trial registries and gray literature (published or unpublished data not readily accessible via main databases) were also searched. DATA SELECTION: The analysis included randomized controlled studies 4 weeks or longer, with a sample size > 10, written in English, using omega-3 for diagnosed bipolar depression or mania. No criteria were set for age, gender, or ethnicity. DATA EXTRACTION: A random-effects model was used. The model analyzed the standard mean difference between treatment and placebo between baseline and endpoint, combining the effect size (Hedges g) data. Funnel plot and heterogeneity analyses (I²) were also performed. DATA SYNTHESIS: The findings of 5 pooled datasets (n = 291) on the outcome of bipolar depression revealed a significant effect in favor of omega-3 (P = .029), with a moderate effect size of 0.34. On the outcome of mania, 5 pooled datasets (n = 291) revealed a nonsignificant effect in favor of omega-3 (P = .099), with an effect size of 0.20. Minor heterogeneity between studies on the outcome of bipolar depression was found (I² = 30%; P = .213), which was not present on the outcome of bipolar mania (I² = 0%; P = .98). Funnel plot symmetry suggested no significant likelihood of publication bias. Meta-regression analysis between sample size and effect size, however, revealed that studies with smaller sample sizes had larger effect sizes (P = .05).
CONCLUSIONS: The meta-analytic findings provide strong evidence that bipolar depressive symptoms may be improved by adjunctive use of omega-3. The evidence, however, does not support its adjunctive use in attenuating mania. © Copyright 2012 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21903025     DOI: 10.4088/JCP.10r06710

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  63 in total

1.  Low unesterified:esterified eicosapentaenoic acid (EPA) plasma concentration ratio is associated with bipolar disorder episodes, and omega-3 plasma concentrations are altered by treatment.

Authors:  Erika Fh Saunders; Aubrey Reider; Gagan Singh; Alan J Gelenberg; Stanley I Rapoport
Journal:  Bipolar Disord       Date:  2015-10-01       Impact factor: 6.744

2.  Omega-3 Fatty Acid Plasma Levels Before and After Supplementation: Correlations with Mood and Clinical Outcomes in the Omega-3 and Therapy Studies.

Authors:  L Eugene Arnold; Andrea S Young; Martha A Belury; Rachel M Cole; Barbara Gracious; Adina M Seidenfeld; Hannah Wolfson; Mary A Fristad
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-02-03       Impact factor: 2.576

3.  Effects of Fish Oil Monotherapy on Depression and Prefrontal Neurochemistry in Adolescents at High Risk for Bipolar I Disorder: A 12-Week Placebo-Controlled Proton Magnetic Resonance Spectroscopy Trial.

Authors:  Robert K McNamara; Jeffrey R Strawn; Max J Tallman; Jeffrey A Welge; L Rodrigo Patino; Thomas J Blom; Melissa P DelBello
Journal:  J Child Adolesc Psychopharmacol       Date:  2020-03-11       Impact factor: 2.576

4.  Tryptophan hydroxylase-2: an emerging therapeutic target for stress disorders.

Authors:  Guo-Lin Chen; Gregory M Miller
Journal:  Biochem Pharmacol       Date:  2013-02-19       Impact factor: 5.858

Review 5.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

Review 6.  Role of perinatal long-chain omega-3 fatty acids in cortical circuit maturation: Mechanisms and implications for psychopathology.

Authors:  Robert K McNamara; Jennifer J Vannest; Christina J Valentine
Journal:  World J Psychiatry       Date:  2015-03-22

7.  First-episode bipolar disorder is associated with erythrocyte membrane docosahexaenoic acid deficits: Dissociation from clinical response to lithium or quetiapine.

Authors:  Robert K McNamara; Ronald Jandacek; Patrick Tso; Thomas J Blom; Jeffrey A Welge; Jeffrey R Strawn; Caleb M Adler; Melissa P DelBello; Stephen M Strakowski
Journal:  Psychiatry Res       Date:  2015-10-09       Impact factor: 3.222

8.  Adolescents with or at ultra-high risk for bipolar disorder exhibit erythrocyte docosahexaenoic acid and eicosapentaenoic acid deficits: a candidate prodromal risk biomarker.

Authors:  Robert K McNamara; Ronald Jandacek; Patrick Tso; Thomas J Blom; Jeffrey A Welge; Jeffrey R Strawn; Caleb M Adler; Stephen M Strakowski; Melissa P DelBello
Journal:  Early Interv Psychiatry       Date:  2015-10-20       Impact factor: 2.732

9.  Abnormal fatty acid pattern in the superior temporal gyrus distinguishes bipolar disorder from major depression and schizophrenia and resembles multiple sclerosis.

Authors:  Robert K McNamara; Therese Rider; Ronald Jandacek; Patrick Tso
Journal:  Psychiatry Res       Date:  2014-01-02       Impact factor: 3.222

Review 10.  Omega-3 Supplementation for Psychotic Mania and Comorbid Anxiety in Children.

Authors:  Anthony T Vesco; Jennifer Lehmann; Barbara L Gracious; L Eugene Arnold; Andrea S Young; Mary A Fristad
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-08-19       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.